Home
Subject Index
Feedback
Health Evidence Bulletins - Wales

Details - Coronoary Heart Disease

Introduction
Chapter 1: Lifestyle
1.1 Mortality rates for coronary heart disease
1.2 Lifestyle measures in Wales
  Obesity
  Fruit and vegetable consumption
  Smoking
  Physical activity
  Alcohol consumption
  1.3  Diabetes
  1.4  Hypertension
  1.5  Hyperlipidaemia
  1.6  Family history of coronary heart disease
  1.7  Smoking
  1.8  Obesity and Overweight
  1.9  Physical activity

top

  Other Lifestyle Factors
  1.10  Alcohol consumption
  1.11  Antioxidants
  1.12  C-reactive protein
  1.13  Coffee
  1.14  Fibrinogen
  1.15  Folate
  1.16  Fruit and vegetable consumption
  1.17  Gout/uric acid
  1.18  Hormone replacement therapy
  1.19  Hyperhomocysteinemia
  1.20  Lycopene
  1.21  Psychosocial factors
  1.22  Ongoing risk factor studies
  1.22  Interventions to prevent or reduce tobacco use at society/community level
  1.24  Interventions to prevent or reduce tobacco use in hospitals
  1.25  Interventions to prevent or reduce tobacco use at the individual level
  1.26  Guidelines - Interventions to reduce tobacco use
  1.27  Interventions to reduce overweight and obesity and promote healthy eating at society/community level
  1.28  Interventions to reduce overweight and obesity and promote healthy eating at the individual level
  1.29  Guidelines for the reduction of overweight and obesity and the promotion of healthy eating
  1.30  Interventions to promote physical activity among the adult population
  1.31  Encouraging young people to be physically active
  1.32  Multiple risk factor interventions
  1.33  Guidelines for the primary prevention of coronary heart disease

top

Chapter 2: High-risk and CHD - diagnosed
2.1  Risk assessment in primary care
  Familial hypercholesterolaemia
  2.2  Screening for familial hypercholesterolaemia
  Interventions for familial hypercholesterolaemia
  Guidelines for the screening and treatment of familial hypercholesterolaemia
  2.3  Risk assessment and treatment in minority population groups
  2.4  Patient information
  2.5  Cholesterol lowering interventions
  Statins in older moderately hypercholesterolemic, hypertensive patients
  Statins and myopathy
  Comparative studies of statins
Recent single statin studies (published from 2000-2003)
  Pravastatin
  Atorvastatin
  Simvastatin
  Ezetimibe
  Statins and fracture rate
  2.6  Dietary and lifestyle interventions for cholesterol reduction

top

  2.7  Cost-effectiveness of cholesterol lowering therapies
  Cost-effectiveness of statin therapy
  2.8  Guidelines for hyperlipidaemia screening and management
  2.9  Hypertension
  Diuretics for hypertension treatment
  Beta-blockers for hypertension treatment
  Vasodilators for hypertension treatment
  Drug therapy for hypertension in older patients
  2.10  Dietary interventions for the management of hypertension
  Alcohol consumption and hypertension
  Weight reduction and hypertension
  Dietary interventions for the management of hypertension in older people (≥ 60 years old)
  2.11  Exercise for the management of hypertension
  2.12  Guidelines for the management of hypertension
  2.13  Management in primary care

top

  2.14  Risk assessment in stable angina
  Stress/exercise testing
  Electron beam computed tomography
  Coronary angiography
  Magnetic resonance imaging
  Stress myocardial perfusion imaging
  New tools for risk assessment
  Antiplatelets & anticoagulants for stable angina/coronary heart disease
  Nitroglycerin for stable angina
  Beta-blockers for stable angina
  ACE-inhibitors for stable angina
  Vasodilators for stable angina
  2.16  Revascularisation versus medical intervention for stable angina/coronary heart disease
  Equity of access to revascularisation
  2.17  Comparisons of revascularisation techniques for stable angina/coronary heart disease
  Cost-effectiveness of revascularisation techniques
  2.18  Therapies before revascularisation for stable angina/coronary heart disease
  2.19  Therapies after revascularisation for stable angina/coronary heart disease
  2.20  Guidelines for coronary revascularisation
  2.21  Angina not controlled by medication or amenable to surgery
  2.22  Guidelines for the management of stable angina

top

Chapter 3: Treatment & Therapy for Acute Coronary Syndromes (ACS)
3.1   Prehospital resuscitation
3.2   Defibrillation
  3.3   Information and advice 
  3.4   Assessment of cardiac damage in the emergency department Troponin and other markers
  NSF Recommendation Question(s)
  3.5   Thrombolysis
  Choice of Thrombolytic
  Magnesium sulphate
  Guidelines for pre-hospital management
  3.6   HeartStart Wales
  3.7   Aspirin, clopidogrel and heparin for acute coronary syndromes 
  3.8   Glycoprotein IIb/IIIa inhibitors for acute coronary syndromes
  3.9   Other post acute ACS therapies
  3.10  Glycoprotein IIb/IIIa blockers in percutaneous coronary intervention
  3.11  Angioplasty versus thrombolysis
  3.12  Choice of operative technique
  3.13  Influenza Vaccination
  3.14  Non-invasive investigation
  3.15  Guidelines and audit standards for the management of acute coronary syndromes

top

  3.16  Cardiac rehabilitation 
  Exercise based rehabilitation
  Smoking cessation
  Psychoeducational programmes
  Outcome measurement and auditing of cardiac rehabilitation programmes
  3.17  Risk stratification at discharge
  3.18  Effect of centre size on angioplasty outcomes
  3.19  Assessment and treatment of heart failure post ACS
  ACE inhibitors to prevent heart failure
  3.20  Secondary prevention
  Discharge policies for secondary prevention
  Primary care management of secondary prevention
  3.21  Aspirin/clopidogrel for secondary prevention
  3.22  Cholesterol control for secondary prevention

top

  Other treatments for secondary prevention
  3.23  Beta-blockers for secondary prevention 
  3.24  Antiarrythmics for secondary prevention. 
  3.25  Anticoagulants for secondary prevention
  3.26  Chelation therapy for secondary prevention
  3.27  Calcium channel blockers  for secondary prevention
  3.28  Brain natriuretic peptide for secondary prevention
  3.29  Dietary advice for secondary prevention
  3.30  Antioxidant vitamins for secondary prevention
  3.31  Guidelines for the long-term management/secondary prevention of acute coronary syndromes 

top

Chapter 4: Heart Failure
4.1  Prevalence and Incidence of heart failure
4.2  Diagnosis/screening/decision aids for general practice
  Echocardiography techniques
  B-type natriuretic peptide (Brain natriuretic peptide)
  Diastolic heart failure
4.3  ACE inhibitors
  ACE inhibitor/ aspirin interactions?
  Underdosing of ACE inhibitors
  Cost-effectiveness of ACE inhibitors
  ACE inhibitors versus angiotensin II receptor blockers.

top

  4.4  ACE inhibition after myocardial infarction
4.5  Diuretics
4.6  Beta-blockers
  4.7  Antiarrythmic therapies
  4.8  Digoxin/digitalis
  4.9  Phosphodiesterase inhibitors
  4.10 Angiotensin receptor blockers
  4.11  Inotropic agents
  4.12  Anticoagulants
  4.13  Calcium channel blockers
  4.14  Spironolactone
  4.15  Crataegus extract
  4.16  General expert advice on choice of drug therapy
  4.17  Non pharmacological therapies
  Surgical revascularisation
  Implantable cardioverter defibrillators and cardiac resynchronisation (by biventricular pacing)
  Left ventricular assist devices
  4.18 Cardiac transplantation
  4.19  Heart failure clinics and specialist staff
  Specialist heart failure nurses
  Appropriate staffing for heart failure care (& clinics)
  Multidisciplinary care programmes    
  Pharmacists
  4.20  Severe heart failure and palliative management
  4.21  Guidelines

top

Chapter 5: Atrial Fibrillation
5.1  Prevalence of atrial fibrillation
5.2  Morbidity, mortality and stroke risk for patients with atrial fibrillation
  5.3  Screening and assessment of atrial fibrillation
  5.4  Cardioversion (electrical or pharmacological) and the maintenance of sinus rhythm
  Rate control versus rhythm control
  Electrical cardioversion
  Pharmacological cardioversion
  Cost-effectiveness studies in cardioversion and maintenance of sinus rhythm
  5.5  The stratification of embolic risk in patients with atrial fibrillation and appropriate management strategies
  Embolic risk assessment in atrial fibrillation
  Therapy to reduce embolic risk in patients with atrial fibrillation
  Cost-effectiveness of anticoagulation management decisions
  Ethnic differences
  5.6  Surgical interventions
  5.7  Evidence-based guidelines
Index
Contributors

top

Home Feedback Subject Index

Health Evidence Bulletins: Wales, Duthie Library, UWCM, Cardiff CF14 4XN. e-mail: mannmk@cf.ac.uk